BeStock  
Markets › Compare › NTLA vs GPCR

NTLA vs GPCR

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
NTLA · Intellia Therapeutics$12.75 ▲ 4.00%
GPCR · Structure Therapeutics$27.59 ▼ 0.29%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

22103185266347Oct 7, '25Apr 7, '26Oct 5, '26
  • NTLA -37.6%
  • GPCR -2.9%

Head to head

MetricNTLAGPCR
Price$12.75$27.59
Change today▲ 4.00%▼ 0.29%
Market cap$1.79B$1.97B
Return, 3 months-26.9%-51.3%
Return, year to date+41.8%-60.3%
Return, 1 year-37.9%-3.8%
P/E (TTM)-3.8-9.1
P/B2.51.5
P/E percentile vs own 5y64th–
Dividend yield––
Revenue growth (YoY, latest qtr)––
Net profit growth (YoY)–-72.2%
Gross margin––
Operating margin––
Net margin––
Return on equity––
Analyst target vs. price+60.8%+283.6%
Analyst buy share50%100%
RSI (14)5717
30-day volatility46.6%64.9%
Max drawdown, 1 year-71.3%-70.6%
Trend readLeaning bullishStrong downtrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • GPCR is the largest of the group by market value.
  • GPCR has returned the most over the past year.
  • GPCR carries the lowest trailing P/E.
  • NTLA has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top